Sign in

ATHE on Nasdaq

ALTERITY THERAPEUTICS LTD

ALTERITY THERAPEUTICS LTD is a pharmaceutical preparations company, listed on Nasdaq (ATHE).1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with KAZIA THERAPEUTICS LTD or Immutep, or pick any stock.

  • TickerATHE on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersC31
  • Incorporated inAustralia2
  • Business addressLevel 15, 500 Collins Street, Melbourne, Vic 30002
  • Filer categoryNon-accelerated filer2

See how the biggest companies compare on our leaderboards

Our legal and commercial name is Alterity Therapeutics Limited (formerly Prana Biotechnology Limited). We were incorporated under the laws of the Commonwealth of Australia on November 11, 1997 and began limited operations shortly thereafter. On April 8, 2019, we changed our name to Alterity Therapeutics Limited. Our registered and principal executive office is located at Level 15, 500 Collins Street, Melbourne, Victoria, 3000, Australia, and our telephone number is +61 3 9349 4906. Our website address is www.alteritytx.com. The information on our website is not incorporated by reference into this annual report.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from. Figures are in AUD, the currency the company reports in.

Financial statements

Net income45678-12.1M AUD in 2025−2% since 2019
-20.0M AUD-15.0M AUD-10.0M AUD-5.0M AUD02019: -12.3M AUD-12.3M AUD20192020: -13.5M AUD-13.5M AUD2020+9%2021: -15.3M AUD-15.3M AUD2021+14%2022: -12.8M AUD-12.8M AUD2022−16%2023: -13.8M AUD-13.8M AUD2023+7%2024: -19.1M AUD-19.1M AUD2024+39%2025: -12.1M AUD-12.1M AUD2025−36%

Every line of the income statement as filed: the last 3 fiscal years, latest first.9

Period ending2026-06-302025-06-302024-06-30
Interest income1.7M AUD446.3K AUD268.4K AUD
Other income3.6M AUD7.6M AUD4.0M AUD
Intellectual property expenses-262.8K AUD-127.5K AUD-214.3K AUD
General and administration expenses-10.5M AUD-5.5M AUD-4.8M AUD
Research and development expenses-17.6M AUD-14.4M AUD-18.6M AUD
Other operating expenses-283.9K AUD-87.3K AUD-5.2K AUD
Other gains / (losses)90.1K AUD-67.1K AUD261.2K AUD
Loss before income tax expense-23.3M AUD-12.1M AUD-19.1M AUD
Income tax expense-113.5K AUD-68.1K AUD-46.1K AUD
Loss for the year-23.4M AUD-12.1M AUD-19.1M AUD
Other comprehensive loss-40.8K AUD0 AUD0 AUD
Total comprehensive loss for the year-23.4M AUD-12.1M AUD-19.1M AUD
Loss per share (basic and diluted - cents per share) (adjusted) (in AUD per share)-11.12 AUD-9.50 AUD-26.20 AUD
Weighted average number of ordinary shares used in computing basic and diluted net loss per share (in shares)210.5M shares127.9M shares73.0M shares

Compare ALTERITY THERAPEUTICS LTD with another company

Corporate structure

ALTERITY THERAPEUTICS LTD sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of ALTERITY THERAPEUTICS LTD

  • JPMorgan Chase Filed SCHEDULE 13G/A on ALTERITY THERAPEUTICS LTD, latest May 5, 2025 (2 filings since May 2, 2025)
  • Life Biosciences LLC Filed SC 13D/A on ALTERITY THERAPEUTICS LTD, latest Oct 31, 2022 (6 filings since Mar 4, 2022)
  • ALTERITY THERAPEUTICS LTD C3

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What ALTERITY THERAPEUTICS LTD reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net3.8K AUD8 Jun 30, 202532.2K AUD8 Jun 30, 2024−88.0%
Operating-lease assets (leased space)151.3K AUD8 Jun 30, 2025154.7K AUD8 Jun 30, 2024−2.2%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents33.2M AUD8 Jun 30, 202512.6M AUD8 Jun 30, 2024+162.4%

Leadership

Who has led ALTERITY THERAPEUTICS LTD, and when. Pick a name to see everywhere that person has worked.

Chief financial officer

  1. Niven Abby Sarah Macnish2026–now
Board members and other officers (4)

Former names

  • PRANA BIOTECHNOLOGY LTDMay 29, 2002 to Apr 8, 20192

Filings

385 filings to the SEC since October 2021: 5 annual reports, 10 insider forms, 8 large holders, 362 other. The latest 20:

  1. Oct 9, 20266-K EDGAR
  2. Oct 5, 20266-K EDGAR
  3. Sep 25, 20266-K EDGAR
  4. Sep 23, 20266-K EDGAR
  5. Sep 18, 2026S-8 EDGAR
  6. Sep 18, 20266-K EDGAR
  7. Sep 16, 20266-K EDGAR
  8. Sep 8, 20264 PRIMARY DOCUMENT EDGAR
  9. Sep 8, 20264 PRIMARY DOCUMENT EDGAR
  10. Sep 8, 20266-K EDGAR
  11. Sep 8, 20266-K EDGAR
  12. Sep 3, 20266-K EDGAR
  13. Sep 2, 20266-K EDGAR
  14. Sep 2, 20266-K EDGAR
  15. Sep 1, 20266-K EDGAR
  16. Aug 31, 20266-K EDGAR
  17. Aug 31, 20266-K EDGAR
  18. Aug 28, 202620-F EDGAR
  19. Aug 28, 20266-K EDGAR
  20. Aug 28, 20266-K EDGAR

The 385 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

1 open-market trades by officers, directors and large owners since October 2021: 1 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 31, 2026Marks Peter AshleyDirectorBuy47,620$0.50$23.8KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Twin Lakes Capital Management, LLC139,258$747.8K0.3%No change
Morgan Stanley63,065$338.7K0.0%+4,683
Greenleaf Trust62,000$332.9K0.0%+30,000
HB Wealth Management, LLC58,460$313.9K0.0%No change
Citadel Advisors LLC37,597$201.9K0.0%+17,520
Bnp Paribas Financial Markets10,239$55.0K0.0%+3,430
GAMMA Investing LLC2,309$12.4K0.0%+453
Rhumbline Advisers2,009$10.8K0.0%+39
Providence Capital Advisors, LLC200$1.1K0.0%New
Integrated Wealth Concepts LLC73$3920.0%New
Osaic Holdings, Inc.68$3620.0%No change
Blue Trust, Inc.40$2150.0%No change
Farther Finance Advisors, LLC39$2050.0%+17
CoreCap Advisors, LLC21$1130.0%No change
Hrt Financial LP17,292$920.0%New
Steward Partners Investment Advisory, LLC6$320.0%No change
UBS Group AG5$270.0%New
Acadian Asset Management LLC1,863$100.0%No change
Cranbrook Wealth Management, LLC1$60.0%New
Danske Bank A/s1$50.0%No change
Citigroup Inc1$50.0%New
Caitong International Asset Management Co., Ltd1$50.0%New

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How ALTERITY THERAPEUTICS LTD is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARALTERITY THERAPEUTICS LTD1
  • CIK0001131343
  • Filer statusNon-accelerated filer not an emerging growth company; not a shell company3
  • Incorporated inAustralia3
  • Fiscal year endsJune 301
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business addressLevel 15, 500 Collins Street, Melbourne, VIC 3000, Australia1
  • Phone61 3 9349 49061
  • Shares outstanding217,508,862 shares as of Jun 30, 20263
  • AuditorPricewaterhouseCoopers, Melbourne, Australia PCAOB ID 1379; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceMay 29, 20021
  • Filings1,165 in all: 6-K (992), 20-F (25), UPLOAD (18), CORRESP (17), EFFECT (13), F-3 (12), SC 13D/A (11), SC 13G/A (11)1
    All 28 form types

    424B5 (8), 424B3 (7), 6-K/A (7), SC 13G (7), 3 (6), S-8 (5), 4 (4), 20-F/A (3), POS AM (3), 20FR12G/A (2), 424B1 (2), F-6EF (2), NT 20-F (2), REGDEX (2), 20FR12G (1), F-6 POS (1), FWP (1), SC 13D (1), SCHEDULE 13G (1), SCHEDULE 13G/A (1)

  • Latest filingsAnnual report (20-F) Aug 28, 2026

Securities registered for trading

ClassSymbolExchange
American Depositary Shares, each representing 12 Ordinary SharesATHENasdaq

From the cover page of the 20-F filed Aug 28, 2026 (Section 12(b) of the Exchange Act).3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17